X-ray CT and pneumonia inhibition properties of gold-silver nanoparticles for targeting MRSA induced pneumonia

Biomaterials

Volumn 35, Issue 25, 2014, Pages 7032-7041

  Huo, Da ^a   Ding, Jing ^c   Cui, Yi X ^a   Xia, Lu Y ^a   Li, Hui ^a   He, Jian ^a   Zhou, Zheng Y ^a   Wang, Hong W ^b   Hu, Yong ^a  

^a NANJING UNIVERSITY   (China)

^b MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^c CHILDREN S HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Anti bacterial; Computed tomography; Gold; Methicillin resistant Staphylococcus aureus; Nanoparticles; Silver

Indexed keywords

ANTIBODIES; BACTERIA; COMPUTERIZED TOMOGRAPHY; ENZYME INHIBITION; GOLD; NANOPARTICLES;

ANTI-BACTERIAL; BIODISTRIBUTIONS; CONTRAST ENHANCEMENT; CYTOKINE PRODUCTION; EARLY-STAGE DIAGNOSIS; INHIBITION PROPERTY; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; NANOPARTICLE (NPS);

SILVER;

BACTERIUM ANTIBODY; GOLD NANOPARTICLE; GOLD SILVER METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS MONOCLONAL ANTIBODY NANOPARTICLE; INTERLEUKIN 6; IOHEXOL; MONOCLONAL ANTIBODY; SILVER NANOPARTICLE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VANCOMYCIN; GOLD; METAL NANOPARTICLE; SILVER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL PNEUMONIA; BACTERIOSTASIS; CELL PROLIFERATION; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG LAVAGE; LUNG PARENCHYMA; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; PRIORITY JOURNAL; RAT; STAPHYLOCOCCAL PNEUMONIA; TRANSMISSION ELECTRON MICROSCOPY; VENTILATOR ASSOCIATED PNEUMONIA; ZETA POTENTIAL; ANIMAL; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PNEUMONIA, BACTERIAL; PROCEDURES; WISTAR RAT;

BACTERIA (MICROORGANISMS); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; RATTUS;

ANIMALS; DRUG DELIVERY SYSTEMS; GOLD; MALE; METAL NANOPARTICLES; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; PNEUMONIA, BACTERIAL; RATS; RATS, WISTAR; SILVER; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84902118108     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.04.092     Document Type: Article

References (39)

1. Davis K.A., Stewart J.J., Crouch H.K., Florez C.E., Hspenthal D.R. Methicillin-resistant staphylococcus aureus (MRSA) nares colonization at hospital admission and its effect on subsequent MRSA infection. Clin Infect Dis 2004, 39:776-782.
2. Tan H.L., Peng Z.X., Li Q.T., Xu X.F., Guo S.R., Tang T.T. The use of quaternised chitosan-loaded PMMA to inhibit biofilm formation and down regulate the virulence-associated gene expression of antibiotic-resistant staphylococcus. Biomaterials 2012, 33:365-377.
3. Arciola C.R., Campoccia D., Speziale P., Montanaro L., Costerton J.W. Biofilm formation in staphylococcus implant infections. A review of molecular mechanisms and implications for biofilm-resistant materials. Biomaterials 2012, 33:5967-5982.
4. James E., Viola H., Hool L., Eggers P.K., Raston C.L., Boulos R.A. Anovel antimicrobial agent reduces oxidative stress in cells. RSC Adv 2013, 3:7277-7281.
5. Graves S.F., Kobayashi S.D., Deleo F.R. Community-associated methicillin-resistant Staphylococcus aureus immune evasion and virulence. JMol Med 2010, 88:109-114.
6. Kobayashi S.D., Deleo F.R. An update on community-associated MRSA virulence. Curr Opin Pharmacol 2009, 9:545-551.
7. Rubensten E., Kollef M.H., Nathwani D. Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008, 46:378-385.
8. Herold B.C., Immergluck L.C., Maranan M.C., Lauderdale D.S., Gaskin R.E., Boyle-Vavra S., et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 1998, 279:593-598.
9. Grrak E.J., Yamada S.M., Brown J.D. Community-acquired methicillin-resistant Staphylococcus aureus in hospitalized adults and children without known risk factors. Clin Infect Dis 1999, 29:797-800.
10. Baba T., Takeuchi F., Kuroda M., Yuzawa H., Aoki K., Oguchi A. Genome and virulence determinants of high virulence community-acquired MRSA. Lancet 2002, 359:1819-1827.
11. Heyland D.K., Cook J., Griffith L., Keenan S.P., Brun-Buisson C. The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. Am J Respir Crit Care Med 1999, 159:1249-1256.
12. Kollef M.H., Silver P., Murphy D.M., Trovillion E. The effect of late-onset ventilator-associated pneumonia in determining patient mortality. CHEST 1995, 108:1655-1662.
13. Schwartz K.L., Nourse C. Panton-valentine leukocidin-associated Staphylococcus aureus necrotizing pneumonia in infants: a report of four cases and review of the literature. Eur J Pediatr 2012, 171:711-717.
14. Marquette C.H., Georges H., Wallet F., Ramon P., Saulnier F., Neviere R., et al. Diagnostic efficiency of endotracheal aspirates with quantitative baderlal cultures in intubated patients with suspended pneumonia. Am Rev Respir Dis 1883, 148:138-144.
15. Torres A., Martos A., Bellacasa J.P.D.L., Ferrer M., Ebiary M.E., Gonzrlez J. Specificity of endotracheal aspiration, proterted specimen brush, and bronchoalveolar lavage in mechanically ventilated patients. Am Rev Respir Dis 1993, 147:952-957.
16. Pugin J., Auckenthaler R., Mili N., Janssens J.P., Lew D., Suter P.M. Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic "blind" bronchoalveolar lavage fluid. Am Rev Respir Dis 1991, 143:1121-1129.
17. Fagon J.Y., Chasrre J., Hance A.J., Guiguet M., Trouillet J.L., Domart Y. Detection of nosocomial lung infection in ventilated patients. Am Rev Respir 1988, 138:110-116.
18. Chastre J., Fagon J.Y. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002, 165:867-903.
19. Wang H., Zheng L., Peng C., Guo R., Shen M.W., Shi X.Y., et al. Computed tomography imaging of cancer cells using acetylated dendrimer-entrapped gold nanoparticles. Biomaterials 2011, 32:2979-2988.
20. Marchiori E., Zanetti G., D'lppolito G., Verrastro C.G.Y., Meirelles G.D.S.P., Capobianco J., et al. Swine-origin influenza A (H1N1) viral infection: thoracic findings on CT. AJR Am J Roentgenol 2011, 196:723-728.
21. Lee K.S., Kullnig P., Hartman T.E., Muller N.L. Cryptogenic organizing pneumonia: CT findings in 43 patients. AJR Am J Roentgenol 1994, 162:543-546.
22. Kami M., Kishi Y., Hamaki T., Kawabata M., Kashima T., Masumoto T., et al. The value of the chest computed tomography halo sign in the diagnosis of invasive pulmonary aspergillosis. an autopsy-based retrospective study of 48 patients. Mycoses 2002, 45:287-294.
23. Hiramatsu K. Vancomycin resistance in staphylococci. Drug Resist Updat 1998, 1:135-150.
24. Burnie J.P., Matthews R.C., Carter T., Beaulieu E., Donohoe M., Chapman C. Identification of an immunodominant ABC transporter in methicillin-resistant Staphylococcus aureus infections. Infect Immun 2000, 68:3200-3209.
25. Huo D., He J., Li H., Shi T.T., Feng Y.H., Zhou Z.Y., et al. Fabrication of Au@Ag core-shell NPs as enhanced CT contrast agents with broad antibacterial properties. Colloid Surf B 2014, 117:29-35.
26. Huo D., Gao J., Guo B.L., Ding Y., He J., Yu H.P., et al. Silver nanoshells as tri-mode bactericidal agents integrating long term antibacterial, photohyperthermia and triggered Ag+ release capabilities. RSC Adv 2013, 3:10632-10638.
27. Satapathy M., Wang L., Zielinski R., Qian W.P., Lipowska M., Capala J., et al. Active targeting using HER-2-antibody-conjugated nanoparticles enabled sensitive and specific imaging of orthotopic HER-2 positive ovarian tumors. Small 2013, 3:544-555.
28. Marquette C.H., Wermert D., Wallet F., Copin M.C., Tonnel A.B. Characterization of an animal model of ventilator-acquired pneumonia. CHEST 1999, 115:200-209.
29. Faure K., Fujimoto J., Shimabukuro D.W., Ajayi T., Shime N., Moriyama K. Effects of monoclonal anti-PcrV antibody on pseudomonas aeruginosa-induced acute lung injury in a rat model. JImmune Based Ther Vaccines 2003, 1:1-9.
30. Yu S.B., Watson A.D. Chem Rev 1999, 99:2353-2377.
31. AshaRani P.V., Low Kah Mun G., Hande M.P., Valiyaveettil S. Cytotoxicity and genotoxicity of silver nanoparticles in human cells. ACS nano 2008, 3:279-290.
32. Balkwill F., Mantovani A. Inflammation and cancer: back to virchow?. Lancet 2001, 357:539-545.
33. Tateda K., Moore T.A., Deng J.C., Newstead M.W., Zeng X.Y., Matsukawa A. Early recruitment of neutrophils determines subsequent T1/T2 host responses in a murine model of Legionella pneumophila pneumonia. JImmunol 2001, 166:3355-3361.
34. Steikraus G., White R., Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S.aureus (MRSA) blood isolates from 2001-05. JAntimicrob Chemother 2007, 60:788-794.
35. Golper T.A., Noonan H.M., Elzinga L., Gilbert D., Brummett R., Anderson J.L., et al. Vancomycin pharmacokinetics, renal handling, and nonrenal clearances in normal human subjects. Clin Pharmacol Ther 1988, 43:565-570.
36. Foster T.J. Immune evasion by staphylococci. Nat Rev Microbiol 2005, 3:948-958.
37. Nizet V. Understanding how leading bacterial pathogens subvert innate immunity to reveal novel therapeutic targets. JAllergy Clin Immunol 2007, 120:13-22.
38. Feuerstein G.Z., Liu T., Barone F.C. Cytokines, inflammation, and brain injury: role of tumor necrosis factor-alpha. Cerebrovasc Brain Metab Rev 1993, 6:341-360.
39. Xing Z., Gauldie J., Cox G., Baumann H., Jordana M., Lei X.F., et al. IL-6 is an anti inflammatory cytokine required for controlling local or systemic acute inflammatory responses. JClin Invest 1998, 101:3-11.